{
    "Clinical Trial ID": "NCT01516736",
    "Intervention": [
        "INTERVENTION 1: ",
        "  LA-EP2006",
        "  During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.",
        "  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.",
        "INTERVENTION 2: ",
        "  Neulasta\u00ae",
        "  During each chemotherapy cycle eligible patients receive Neulasta\u00ae s.c. post chemotherapy application.",
        "  Neulasta\u00ae: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  histologically proven breast cancer",
        "  eligible for six cycles of neoadjuvant or adjuvant chemotherapy",
        "Exclusion Criteria:",
        "  concurrent or prior chemotherapy for breast cancer",
        "  concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy",
        "  concurrent prophylactic antibiotics",
        "  previous therapy with any G-CSF (granulocyte-colony stimulating factor) product",
        "  Other protocol-defined inclusion/exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy",
        "  Mean duration of severe neutropenia, defined as number of consecutive days with ANC <0.5 \u00d7 10^9/l (grade 4 neutropenia).",
        "  Time frame: 21 days (Cycle 1 of chemotherapy treatment)",
        "Results 1: ",
        "  Arm/Group Title: LA-EP2006",
        "  Arm/Group Description: During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.",
        "  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.",
        "  Overall Number of Participants Analyzed: 155",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  FAS: 151 participants",
        "  1.36         (1.133)",
        "  PP: 148 participants",
        "  1.34         (1.141)",
        "Results 2: ",
        "  Arm/Group Title: Neulasta  ",
        "  Arm/Group Description: During each chemotherapy cycle eligible patients receive Neulasta   s.c. post chemotherapy application.",
        "  Neulasta  : Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.",
        "  Overall Number of Participants Analyzed: 153",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  FAS: 149 participants",
        "  1.19         (0.984)",
        "  PP: 144 participants",
        "  1.19         (0.991)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 29/155 (18.71%)",
        "  Febrile neutropenia  16/155 (10.32%)",
        "  Neutropenia  4/155 (2.58%)",
        "  Thrombocytopenia  1/155 (0.65%)",
        "  Anemia  1/155 (0.65%)",
        "  Atrial fibrillation  0/155 (0.00%)",
        "  Cardiac arrest  1/155 (0.65%)",
        "  Cardio-respiratory arrest  1/155 (0.65%)",
        "  Pericardial hemorrhage  1/155 (0.65%)",
        "  Eye irritation  0/155 (0.00%)",
        "  Abdominal pain  3/155 (1.94%)",
        "Adverse Events 2:",
        "  Total: 32/153 (20.92%)",
        "  Febrile neutropenia  19/153 (12.42%)",
        "  Neutropenia  6/153 (3.92%)",
        "  Thrombocytopenia  1/153 (0.65%)",
        "  Anemia  0/153 (0.00%)",
        "  Atrial fibrillation  1/153 (0.65%)",
        "  Cardiac arrest  0/153 (0.00%)",
        "  Cardio-respiratory arrest  0/153 (0.00%)",
        "  Pericardial hemorrhage  0/153 (0.00%)",
        "  Eye irritation  1/153 (0.65%)",
        "  Abdominal pain  5/153 (3.27%)"
    ]
}